CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 02 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 20 Aug 2015 Planned initiation date changed from 1 Apr 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record
- 17 Feb 2015 Planned initiation date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.